GLP-1 Tolerability and Adherence
The Pharmacokinetic Case Against Weekly Bolus Dosing in GLP-1 Tolerability
Smoother drug release could separate GLP-1's appetite suppression from nausea.
Marcus Tully-Byrne
· 8 min read
Route of Administration
Nanoparticle Platforms in Clinical and Preclinical Development for Intranasal CNS Delivery
Lipid and polymeric carriers show the most promise for delivering brain drugs through the nose.
Priya Venkatesan
Nanoparticle Scale-Up From Lab Bench to GMP Manufacturing
Controlling particle physics, not just batch volume, keeps nanoparticles consistent at scale.
Tobias Mehring
Nanoparticle Surface Functionalization for Blood-Brain Barrier Crossing
Ligand choice and particle chemistry must match the barrier's biology to reach the brain.
Séverine Okafor
University Spinouts With Foundational Patent Estates in Nanoparticle Peptide Delivery
University spinouts may control GLP-1 delivery through foundational nanoparticle patents.
Marcus Tully-Byrne
Exosome and Extracellular Vesicle Platforms for CNS Peptide Delivery
Exosomes could deliver brain peptides by mimicking cells' natural transport.
Marcus Tully-Byrne
Nanoparticle Size and Zeta Potential Effects on in Vivo Behavior
Tuning particle size and charge unlocks direct brain delivery through nasal routes.
Tobias Mehring
Regulatory Classification of Nanoparticle Drug Products at the FDA
The FDA uses existing drug and biologic frameworks to evaluate nanoparticle products.
Priya Venkatesan